Biodesix, Inc. (BDSX)
| Market Cap | 115.56M |
| Revenue (ttm) | 41.64M |
| Net Income (ttm) | -66.10M |
| Shares Out | 78.61M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,252 |
| Open | 1.50 |
| Previous Close | 1.48 |
| Day's Range | 1.43 - 1.50 |
| 52-Week Range | 0.96 - 2.53 |
| Beta | 1.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2023 |
About BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer... [Read more]
Financial Performance
In 2022, Biodesix's revenue was $38.21 million, a decrease of -29.89% compared to the previous year's $54.51 million. Losses were -$65.45 million, 51.6% more than in 2021.
Financial StatementsNews
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that two abstr...
Biodesix to Participate in Two Upcoming Investor Conferences in September
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, ...
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new ana...
Biodesix Announces Second Quarter 2023 Results and Highlights
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial ...
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hut...
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r...
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prosp...
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Cente...
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large...
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new...
Biodesix to Participate in William Blair's 43rd Annual Growth Stock Conference
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hut...
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in fou...
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. a leading diagnostics company, is proud to announce that its Chief Financial Officer, Robin Harper Cowie, has been appointed to...
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility...
Biodesix Announces First Quarter 2023 Results and Highlights
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial ...
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r...
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial ...
Biodesix to Participate at Cowen's 43rd Annual Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hut...
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r...
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four...
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T....
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leadin...
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten publi...
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public...
Biodesix Announces Proposed Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten...